In a plenary talk about cancer genomics at last week's 100th Annual Meeting of the American Association for Cancer Research, Eric Lander, founding director of the Broad Institute, said he hopes to see complete cancer genome analyses become a routine part of oncology research within five years and a standard of care for patients within 10 years.

As the 44th annual meeting of the European Association for the Study of the Liver (EASL) swung into high gear Thursday, data from Anadys Pharmaceuticals Inc., Schering-Plough Corp. and Salix Pharmaceuticals Ltd. garnered headlines. (BioWorld Today)

Biogen Idec Inc. beat analyst expectations for earnings in the first quarter of 2009, but product revenues fell short across the board, and Tysabri once again showed slower-than-anticipated growth. (BioWorld Today)

Dendreon Corp.'s much-anticipated confirmatory Phase III trial of prostate cancer vaccine Provenge (sipuleucel-T) met its primary endpoint of improving overall survival, potentially ending the drug's two-year regulatory roller coaster ride and paving the way for the first FDA approval of a therapeutic cancer vaccine. (BioWorld Today)

While the FDA reviews a new drug application for Solzira (gabapentin enacarbil) in restless legs syndrome, XenoPort Inc. exercised its option to co-promote the drug in the U.S. with partner GlaxoSmithKline plc. (BioWorld Today)